StockData
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. (GOVX) shareholders

GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$2.01−0.01 (-0.50%)

Close on Nov 17, 2026Market cap $14.81MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
6.7%
0M of 7M shares
Institutional holders
17
5 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Waqas Khatri
Joint filing with Ayrton Capital LLC (9.99%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%)
4,810,4519.99%13G (passive)Dec 31, 2025
Mitchell P. Kopin
Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%)
2,849,3449.99%13G (passive) amendmentSep 30, 2025
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
291,1559.99%13G (passive) amendmentMar 31, 2026
Intracoastal Capital LLC
Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%)
233,3379.99%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GOVXValueChange% of portfolio
Jane Street Group, LLC315,2754.28%$400.40KNew0.00%
Hrt Financial LP126,7041.72%$160.00KNew0.00%
Geode Capital Management, LLC21,1120.29%$26.81K−14,9640.00%
Two Sigma Securities, LLC10,6820.14%$13.57KNew0.00%
Vanguard Fiduciary Trust Co5,0680.07%$6.44K–0.00%
Tower Research Capital LLC (TRC)3,5020.05%$4.45K−250.00%
Vanguard Capital Management LLC3,2170.04%$4.09K–0.00%
SBI Securities Co., Ltd.2,5880.04%$3.29K+2,2040.00%
Morgan Stanley2,0030.03%$2.54K+1,9970.00%
Jones Financial Companies Lllp1,0000.01%$1.32KNew0.00%
UBS Group AG9440.01%$1.20K−3,3040.00%
BlackRock, Inc.8420.01%$1.07K−2510.00%
Citigroup Inc2300.00%$292New0.00%
Wells Fargo & Company/Mn300.00%$38−10.00%
Danske Bank A/S30.00%$4–0.00%
FMR LLC10.00%$1–0.00%
Royal Bank of Canada10.00%$0–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026170M6.7%5 / 25 / 40M0M
Q1 2026160M4.5%15 / 10 / 00M0M
Q4 202510M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held GOVX in Q2 2026, 12% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GOVXValue% of fundAs of
Fidelity Extended Market Index Fund22,2450.30%$45.82K0.00%May 31, 2026
Vanguard Extended Market Index Fund3,2170.04%$4.09K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund8560.01%$1.76K0.00%May 31, 2026
Fidelity Total Market Index Fund5760.01%$1.19K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
David A. DoddPresident, CEO, Director36,6610.50%Jun 22, 2026
John W. SharkeyVP, Business Development6,1910.08%Jun 22, 2026
Kelly T. McKee Jr.Chief Medical Officer3,4940.05%Jun 22, 2026
Mark J. NewmanChief Scientific Officer3,0000.04%Jun 22, 2026
Mark ReynoldsCFO14,0130.19%Jun 22, 2026
Manpreet UppalDirector––Nov 3, 2026
Steven Collier BrownDirector––Nov 3, 2026
Randal D. ChaseDirector36,6130.50%Jun 22, 2026
Dean G. KollintzasDirector11,9870.16%Jun 22, 2026
John N. Spencer JrDirector21,4020.29%Jun 22, 2026
Nicole LemerondDirector––Jun 22, 2026
Jayne MorganDirector––Jun 22, 2026
Robert T. McNallyDirector66,2800.90%Jun 22, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
John N. Spencer Jr
Director
Oct 17, 2025Buy+10,000$0.55$5.50K21,402
Kelly T. McKee Jr.
Chief Medical Officer
Aug 7, 2025Buy+1,107$0.67$7423,494
John N. Spencer Jr
Director
Apr 10, 2025Buy+10,000$0.98$9.80K11,402
John W. Sharkey
VP, Business Development
Apr 10, 2025Buy+6,000$0.99$5.94K6,191
David A. Dodd
President, CEO, Director
Apr 1, 2025Buy+10,000$1.08$10.80K36,661
Mark Reynolds
CFO
Mar 31, 2025Buy+6,800$1.08$7.34K14,013
David A. Dodd
President, CEO, Director
Aug 9, 2024Buy+8,000$1.95$15.60K26,661
David A. Dodd
President, CEO, Director
Feb 22, 2024Buy+8,209$2.27$18.63K18,661
David A. Dodd
President, CEO, Director
Feb 21, 2024Buy+520$2.15$1.12K10,452
Mark Reynolds
CFO
Feb 7, 2024Buy+2,000$2.77$5.54K7,213
Kelly T. McKee Jr.
Chief Medical Officer
Dec 22, 2023Buy+6,944$0.36$2.50K35,782
Kelly T. McKee Jr.
Chief Medical Officer
Sep 25, 2023Buy+9,653$0.52$5.02K28,838
David A. Dodd
President, CEO, Director
Aug 25, 2023Buy+35,087$0.57$20.00K148,957
Mark Reynolds
CFO
Aug 18, 2023Buy+10,000$0.52$5.20K78,184
David A. Dodd
President, CEO, Director
Apr 24, 2023Buy+32,000$0.64$20.48K113,870
Mark Reynolds
CFO
Apr 20, 2023Buy+8,000$0.63$5.04K68,184
Randal D. Chase
Director
Sep 21, 2022Buy+10,000$1.10$11.00K36,613
John W. Sharkey
VP, Business Development
Jul 1, 2022Buy+1,000$0.82$8202,860
Kelly T. McKee Jr.
Chief Medical Officer
Jun 27, 2022Buy+4,464$1.12$5.00K19,185
Randal D. Chase
Director
Jun 21, 2022Buy+10,000$1.21$12.10K26,613
Kelly T. McKee Jr.
Chief Medical Officer
May 5, 2022Buy+9,722$0.72$7.00K14,721
Kelly T. McKee Jr.
Chief Medical Officer
May 4, 2022Buy+4,999$0.71$3.55K4,999
Randal D. Chase
Director
Sep 29, 2020Buy+16,613$5.00$83.07K16,613
Mark Reynolds
CFO
Sep 29, 2020Buy+60,184$5.00$300.92K60,184
David A. Dodd
President, CEO, Director
Sep 29, 2020Buy+81,870$5.00$409.35K81,870
Dean G. Kollintzas
Director
Sep 29, 2020Buy+11,987$5.00$59.94K11,987
Robert T. McNally
Director
Sep 29, 2020Buy+53,925$5.00$269.63K53,925
John N. Spencer Jr
Director
Sep 29, 2020Buy+21,024$5.00$105.12K21,024
Randal D. Chase
Director
May 5, 2015Buy+200$0.19$3840,000
Randal D. Chase
Director
May 5, 2015Buy+9,800$0.19$1.86K39,800
Mark Reynolds
CFO
Apr 23, 2015Buy+10,000$0.18$1.80K66,000
Mark Reynolds
CFO
Apr 22, 2015Buy+10,000$0.17$1.70K46,000
Mark Reynolds
CFO
Apr 22, 2015Buy+10,000$0.17$1.70K56,000
John N. Spencer Jr
Director
Apr 20, 2015Buy+18,000$0.17$3.06K46,625
Randal D. Chase
Director
Apr 20, 2015Buy+30,000$0.17$5.10K30,000
Harriet L. Robinson
Chief Scientific Officer, Director
Jun 5, 2013Gift−27,500––1,173,726
Mark Reynolds
CFO
Jan 31, 2012Buy+15,000$0.67$10.05K36,000
Steven S. Antebi
Director
Jan 16, 2012Buy+30,000$0.67$20.10K30,000
John N. Spencer Jr
Director
Dec 30, 2011Buy+14,925$0.67$10.00K28,625
Dean G. Kollintzas
Director
Dec 30, 2011Buy+14,925$0.67$10.00K14,925
David A. Dodd
Director
Dec 30, 2011Buy+112,000$0.67$75.04K127,725
Robert T. McNally
President/CEO, Director
Dec 30, 2011Buy+29,850$0.67$20.00K29,850
Mark Reynolds
CFO
Dec 30, 2011Buy+15,000$0.67$10.05K21,000
Harriet L. Robinson
Chief Scientific Officer, Director
Dec 30, 2011Buy+149,254$0.67$100.00K1,201,226
Harriet L. Robinson
Chief Scientific Officer, Director
Jun 22, 2011Gift−7,422––1,051,972
Harriet L. Robinson
Chief Scientific Officer, Director
Jan 6, 2011Gift−9,714––1,059,394
Harriet L. Robinson
Chief Scientific Officer, Director
Dec 20, 2010Gift−33,333––1,069,108
Robert T. McNally
President & CEO, Director
Oct 15, 2010Gift−8,300––0
Mark Reynolds
Chief Financial Officer
Jul 2, 2010Buy+1,000$2.50$2.50K6,000
Mark J. Newman
VP, Research & Development
Jun 11, 2010Buy+2,000$3.32$6.64K3,000
Mark J. Newman
VP, Research & Development
Jun 11, 2010Buy+1,000$3.25$3.25K1,000
Harriet L. Robinson
Chief Scientific Officer, Director
Jun 10, 2010Buy+2,100$3.35$7.04K1,102,441
Harriet L. Robinson
Chief Scientific Officer, Director
Jun 10, 2010Buy+3,000$3.30$9.90K1,100,341
Robert T. McNally
President & CEO, Director
Jun 10, 2010Buy+300$3.30$9908,300
Donald G. Hildebrand
Director
Jun 9, 2010Buy+1,000$3.29$3.29K19,000
Robert T. McNally
President & CEO, Director
Jun 9, 2010Buy+100$3.30$3307,100
Robert T. McNally
President & CEO, Director
Jun 9, 2010Buy+900$3.32$2.99K8,000
Mark Reynolds
Chief Financial Officer
Jun 9, 2010Buy+530$3.35$1.78K5,000
Mark Reynolds
Chief Financial Officer
Jun 9, 2010Buy+570$3.34$1.90K4,470
Mark Reynolds
Chief Financial Officer
Jun 9, 2010Buy+1,004$3.29$3.30K3,900

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.45%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-34.9%
From 0M shares
Short volume, 20 days
43.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GeoVax Labs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 372,671 shares on Oct 6, 2026 over the last 90 days.

See a number that looks wrong?